{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:58:45Z","timestamp":1791939525203,"version":"4.3.4"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23-AI127935"],"award-info":[{"award-number":["K23-AI127935"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Limited data exist regarding the efficacy of piperacillin-tazobactam (TZP) for the management of nonbacteremic pyelonephritis caused by extended-spectrum \u03b2-lactamase (ESBL)-producing organisms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a multicenter observational study comparing clinical outcomes of adults hospitalized with ESBL-producing pyelonephritis who were receiving TZP versus carbapenems, using an inverse probability of treatment weighted propensity score analysis. Patients were eligible for inclusion if all of the following criteria were met: (1) urine cultures growing Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, or Proteus mirabilis at \u226550 000 colony-forming units\/mL; (2) identification of an ESBL gene; (3) pyuria (\u226510 white blood cells per high powered field in the urine); and (4) dysuria and fever plus at least 1 of the following symptoms: emesis, rigors, hypotension, or flank pain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 186 patients included in the propensity score\u2013weighted cohort; 45 (24%) received TZP and 141 (76%) received a carbapenem. Of these 186 patients, 27% were admitted to the intensive care unit, 48% were immunocompromised, and 45% had underlying urologic abnormalities. There were no differences between the 2 groups in the proportion of patients (20% vs 25%) with recurrent cystitis or pyelonephritis with the same ESBL-producing organism within 30 days (odds ratio, 0.75; 95% confidence interval, .31\u20131.81; P = .52). There were no differences in the resolution of clinical symptoms by Day 7 or in 30-day mortality. There was 1 (2%) patient in the TZP arm and 11 (8%) patients in the carbapenem arm who had incident carbapenem-resistant organisms isolated within 30 days (P = .09).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>TZP may be a reasonable alternative to carbapenems for the management of ESBL-producing pyelonephritis and may mitigate the risk of emergence of carbapenem-resistant organisms, compared with carbapenem therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz1205","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T20:12:16Z","timestamp":1576699936000},"page":"e331-e337","source":"Crossref","is-referenced-by-count":58,"title":["Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum \u03b2-Lactamase\u2013Producing Organisms?"],"prefix":"10.1093","volume":"71","author":[{"given":"Sima L","family":"Sharara","sequence":"first","affiliation":[{"name":"The Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Amoah","sequence":"additional","affiliation":[{"name":"The Johns Hopkins University School of Medicine, Department of Pediatrics, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi D","family":"Pana","sequence":"additional","affiliation":[{"name":"European University of Cyprus, Department of Medicine, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J","family":"Simner","sequence":"additional","affiliation":[{"name":"The Johns Hopkins University School of Medicine, Department of Pathology, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"The Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranita D","family":"Tamma","sequence":"additional","affiliation":[{"name":"The Johns Hopkins University School of Medicine, Department of Pediatrics, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"2020110510415135600_CIT0001","first-page":"933","article-title":"Diagnosis and management of acute pyelonephritis in adults","volume":"71","author":"Ramakrishnan","year":"2005","journal-title":"Am Fam Physician"},{"key":"2020110510415135600_CIT0002","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s15010-018-1148-y","article-title":"Clinical patterns, epidemiology and risk factors of community-acquired urinary tract infection caused by extended-spectrum beta-lactamase producers: a prospective hospital case-control study","volume":"46","author":"Almomani","year":"2018","journal-title":"Infection"},{"key":"2020110510415135600_CIT0003","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s15010-011-0132-6","article-title":"Extended-spectrum \u03b2-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy","volume":"39","author":"Meier","year":"2011","journal-title":"Infection"},{"key":"2020110510415135600_CIT0004","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"2020110510415135600_CIT0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1017\/ice.2015.239","article-title":"Increasing incidence of extended-spectrum \u03b2-lactamase-producing Escherichia coli in community hospitals throughout the southeastern United States","volume":"37","author":"Thaden","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020110510415135600_CIT0006","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1017\/ice.2017.156","article-title":"Incidence of extended-spectrum \u03b2-lactamase (ESBL)-producing Escherichia coli and Klebsiella infections in the United States: a systematic literature review","volume":"38","author":"McDanel","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020110510415135600_CIT0007","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.01896-13","article-title":"Contemporary diversity of \u03b2-lactamases among Enterobacteriaceae in the nine US census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent \u03b2-lactamase groups","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110510415135600_CIT0008","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/jac\/45.6.895","article-title":"Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns","volume":"45","author":"Saurina","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2020110510415135600_CIT0009","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.diagmicrobio.2014.03.026","article-title":"In vitro susceptibility and distribution of beta-lactamases in Enterobacteriaceae causing intra-abdominal infections in North America 2010-2011","volume":"79","author":"Hoban","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"10","key":"2020110510415135600_CIT0010","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cix606","article-title":"Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: results from the increment cohort","volume":"65","author":"Palacios-Baena","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020110510415135600_CIT0011","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/jac\/dkv502","article-title":"Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study","volume":"71","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020110510415135600_CIT0012","first-page":"1319","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020110510415135600_CIT0013","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2020110510415135600_CIT0014","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00365-16","article-title":"A multinational, preregistered cohort study of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"60","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2020110510415135600_CIT0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.medmal.2015.03.003","article-title":"Non-carbapenem therapy of urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"45","author":"de La Blanchardiere","year":"2015","journal-title":"Med Mal Infect"},{"key":"2020110510415135600_CIT0016","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2014.08.018","article-title":"Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"29","author":"Asakura","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2020110510415135600_CIT0017","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli","volume":"17","author":"Seo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2020110510415135600_CIT0018","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00381-05","article-title":"Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species","volume":"50","author":"Gavin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110510415135600_CIT0019","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1093\/jac\/dku215","article-title":"The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"69","author":"Park","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020110510415135600_CIT0020","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijantimicag.2016.12.017","article-title":"Role of piperacillin\/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"49","author":"Yoon","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2020110510415135600_CIT0021","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020110510415135600_CIT0022","article-title":"JHH-BMC for antibiotic use app","author":"Cosgrove","year":"2019","journal-title":"Unbound Med"},{"key":"2020110510415135600_CIT0023","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European society for microbiology and infectious diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020110510415135600_CIT0024","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjmed.2017.01.025","article-title":"A seven-day course of TMP-SMX may be as effective as a seven-day course of ciprofloxacin for the treatment of pyelonephritis","volume":"130","author":"Fox","year":"2017","journal-title":"Am J Med"},{"key":"2020110510415135600_CIT0025","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/01.ju.0000106191.11936.64","article-title":"Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis","volume":"171","author":"Talan","year":"2004","journal-title":"J Urol"},{"key":"2020110510415135600_CIT0026","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"2020110510415135600_CIT0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"key":"2020110510415135600_CIT0028","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/003655401750173922","article-title":"Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime","volume":"33","author":"Cronberg","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"2020110510415135600_CIT0029","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2019.04.012","article-title":"In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016","volume":"54","author":"Karlowsky","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2020110510415135600_CIT0030"},{"key":"2020110510415135600_CIT0031","doi-asserted-by":"crossref","first-page":"ofz027","DOI":"10.1093\/ofid\/ofz027","article-title":"Risk factors for development of carbapenem resistance among Gram-negative rods","volume":"6","author":"Richter","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020110510415135600_CIT0032","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/jac\/dkw590","article-title":"Factors associated with carriage of carbapenem-non-susceptible Enterobacteriaceae in North-Eastern France and outcomes of infected patients","volume":"72","author":"Muggeo","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020110510415135600_CIT0033","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/IDR.S192540","article-title":"Epidemiology of carbapenem-resistant Enterobacteriaceae: a 5-year experience at a tertiary care hospital","volume":"12","author":"Chotiprasitsakul","year":"2019","journal-title":"Infect Drug Resist"},{"key":"2020110510415135600_CIT0034","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/cid\/cis534","article-title":"The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat?","volume":"55","author":"Cai","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020110510415135600_CIT0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/clinids\/22.1.91","article-title":"Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women","volume":"22","author":"Ik\u00e4heimo","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2020110510415135600_CIT0036","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/oxfordjournals.aje.a010170","article-title":"Risk factors for second urinary tract infection among college women","volume":"151","author":"Foxman","year":"2000","journal-title":"Am J Epidemiol"},{"key":"2020110510415135600_CIT0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","article-title":"Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect Dis Clin North Am"},{"key":"2020110510415135600_CIT0038","first-page":"1655","article-title":"Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections","volume":"61","author":"Cai","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020110510415135600_CIT0039","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2318-14-30","article-title":"Antimicrobial resistance in urinary pathogens among Swedish nursing home residents remains low: a cross-sectional study comparing antimicrobial resistance from 2003 to 2012","volume":"14","author":"Sundvall","year":"2014","journal-title":"BMC Geriatr"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz1205\/31947412\/ciz1205.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/8\/e331\/34138167\/ciz1205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/8\/e331\/34138167\/ciz1205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T15:42:48Z","timestamp":1604590968000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/8\/e331\/5681794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,12,20]]},"published-print":{"date-parts":[[2020,11,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz1205","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,15]]},"published":{"date-parts":[[2019,12,20]]}}}